revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
Company profile
Ticker
RVMD
Exchange
Website
CEO
Mark Goldsmith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Warp Drive Bio, Inc. • EQRx, LLC • EQRx UK Limited • EQRx International, Inc. • Verum Norte Therapeutics, Inc. ...
IRS number
472029180
RVMD stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
4 Mar 24
S-8
Registration of securities for employees
26 Feb 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
26 Feb 24
8-K
Results of Operations and Financial Condition
9 Jan 24
8-K/A
Financial Statements and Exhibits
22 Dec 23
CERT
Certification of approval for exchange listing
16 Nov 23
8-A12B
Registration of securities on exchange
15 Nov 23
8-K
Completion of Acquisition or Disposition of Assets
9 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
Transcripts
RVMD
Earnings call transcript
2023 Q4
26 Feb 24
RVMD
Earnings call transcript
2023 Q3
6 Nov 23
RVMD
Earnings call transcript
2023 Q2
8 Aug 23
RVMD
Earnings call transcript
2023 Q1
8 May 23
RVMD
Earnings call transcript
2022 Q4
27 Feb 23
RVMD
Earnings call transcript
2022 Q3
8 Nov 22
RVMD
Earnings call transcript
2022 Q2
10 Aug 22
RVMD
Earnings call transcript
2022 Q1
10 May 22
RVMD
Earnings call transcript
2021 Q4
1 Mar 22
RVMD
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
4
MARK A GOLDSMITH
12 Apr 24
4
Sushil Patel
12 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
3
Lin Wei
29 Mar 24
4
Jeff Cislini
28 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Jeff Cislini
20 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 360.79 mm | 360.79 mm | 360.79 mm | 360.79 mm | 360.79 mm | 360.79 mm |
Cash burn (monthly) | 7.38 mm | (no burn) | 41.08 mm | 30.74 mm | 33.50 mm | 24.32 mm |
Cash used (since last report) | 50.62 mm | n/a | 281.86 mm | 210.92 mm | 229.83 mm | 166.83 mm |
Cash remaining | 310.17 mm | n/a | 78.93 mm | 149.87 mm | 130.96 mm | 193.96 mm |
Runway (months of cash) | 42.0 | n/a | 1.9 | 4.9 | 3.9 | 8.0 |
Institutional ownership, Q3 2023
80.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 44 |
Closed positions | 14 |
Increased positions | 59 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 3.09 tn |
Total shares | 132.60 mm |
Total puts | 330.24 k |
Total calls | 611.30 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Wellington Management | 10.57 mm | $292.65 bn |
Vanguard | 9.64 mm | $266.93 bn |
BLK Blackrock | 8.87 mm | $245.56 bn |
Biotechnology Value Fund L P | 7.56 mm | $188.66 mm |
EcoR1 Capital | 5.58 mm | $154.40 bn |
T. Rowe Price | 5.09 mm | $140.68 bn |
Nextech Invest | 4.84 mm | $133.96 bn |
BBBOF BB Biotech | 4.78 mm | $0.00 |
BLVGF Bellevue | 4.72 mm | $130.69 bn |
Boxer Capital | 4.68 mm | $129.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 24 | Sushil Patel | Common Stock | Sell | Dispose S | No | Yes | 37 | 2,155 | 79.74 k | 15,700 |
10 Apr 24 | Sushil Patel | Common Stock | Option exercise | Acquire M | No | Yes | 16.8 | 2,155 | 36.20 k | 17,855 |
10 Apr 24 | Sushil Patel | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 16.8 | 2,155 | 36.20 k | 34,645 |
10 Apr 24 | Goldsmith Mark A | Common Stock | Sell | Dispose S | Yes | Yes | 35.3374 | 5,000 | 176.69 k | 30,424 |
10 Apr 24 | Goldsmith Mark A | Common Stock | Sell | Dispose S | Yes | Yes | 35.3317 | 5,000 | 176.66 k | 30,424 |
10 Apr 24 | Goldsmith Mark A | Common Stock | Sell | Dispose S | No | Yes | 35.4829 | 7,500 | 266.12 k | 452,879 |
27 Mar 24 | Jeff Cislini | Common Stock | Sell | Dispose S | No | Yes | 31.515 | 800 | 25.21 k | 54,374 |
27 Mar 24 | Jeff Cislini | Common Stock | Sell | Dispose S | No | Yes | 30.3843 | 700 | 21.27 k | 55,174 |
18 Mar 24 | Stephen Michael Kelsey | Common Stock | Sell | Dispose S | No | Yes | 31.5832 | 2,123 | 67.05 k | 270,909 |
News
Top 3 Health Care Stocks That May Collapse In Q2
12 Apr 24
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $45
12 Apr 24
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $46
12 Apr 24
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
10 Apr 24
Raymond James Upgrades Revolution Medicines to Strong Buy, Raises Price Target to $48
10 Apr 24
Press releases
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
9 Apr 24
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
8 Apr 24
Revolution Medicines to Participate in Upcoming Investor Conferences
4 Apr 24